ClinicalTrials.gg
RecruitingNCT05423262Updated Oct 8, 2026

A Study of TRK-950 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of TRK-950 and TRK-950 in Solid Tumor and Melanoma, sponsored by Toray Industries, Inc. Recruiting at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Toray Industries, Inc · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Melanoma with a site in Japan — 9 open to participants now, 19 under way, 3 of them phase 3. Melanoma · Japan.

Planned enrollment
48th of 62
49 · median 156
Started
2022
with 4 others
Phase 1/2
10 of 65
5 open now
Primary completion
2028-03
later than 11 of 18 live
Registered
50th of 65
by date

Among the 65 studies in Melanoma with a site in Japan, this one is the 48th largest by planned enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2022, is one of 10 in phase 1/2, reaches primary completion later than 11 of the 18 other live ones, and was the 50th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

9 of the 65 studies in Melanoma with a site in Japan are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Melanoma with a site in Japan, or all of them as a file.
02

Study summary

Part 1

  • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors

Part 2

  • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy

Part 3

  • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists
Read the detailed description

This is an open-label phase I/II study and consists of three parts. In Part 1, patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who have been refractory or intolerant to standard therapies or for whom no standard therapy exists will receive two dose level of TRK-950. In Part 2, patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who are eligible for standard therapy with NIVO 240 mg alone administered at 2-week intervals will receive two dose level of TRK-950 in combination with Nivolumab. In Part 3, patients with histologically confirmed locally advanced unresectable or metastatic melanoma (excluding uveal melanoma), who received prior chemotherapy with DTIC and for whom no standard therapy exists will receive one dose level of TRK-950. The objectives of this study are to determine the safety, tolerability, pharmacokinetic (PK) profile and the incidence of the development of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against TRK-950.

03

Conditions studied

  • Solid Tumor
  • Melanoma

Browse trials for

Keywords

  • Nivolumab-eligible solid tumor
  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: Patients with and cytologically confirmed locally advanced or solid tumors who have been or intolerant to standard therapies or for whom no standard therapy exists. Part 2: Patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who are eligible for standard therapy with NIVO 240 mg alone administered at 2-week intervals.
  • Part 3: Patients with histologically confirmed locally advanced unresectable or metastatic melanoma (excluding uveal melanoma), who received prior chemotherapy with DTIC and for whom no standard therapy exists
  • Patients with of at least 3 months after the start of study drug administration
  • Patients aged >=18 years at the time of consent
  • Patients who are able to provide written consent in person to be a subject of this study
  • A negative pregnancy test before enrollment (if female of )

Exclusion criteria

Exclusion Criteria:

  • Patients with active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
  • Pregnant women (including those who are considered possibly pregnant based on history taking, etc. by physician) or breastfeeding women (interrupting breastfeeding to enroll is also not allowed)
  • Patients who are unwilling or unable to comply with the protocol specified procedures
  • Patients who are positive for (HIV) antibody
  • Patients who meet any of the following conditions on virus (HBV) and virus (HCV) testing

    • Patients who are positive for hepatitis B surface antigen (HBsAg)
    • Patients who are positive for HCV RNA
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    Part 1 : TRK-950

    * Solid Tumor * TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. Two dose levels will be explored during this Arm.

    Biological: TRK-950

  • Experimental
    Part 2 Cohort 1: TRK-950+Nivolumab

    * Nivolumab-eligible solid tumor * Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1, 8, 15 and 22. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion.

    Biological: TRK-950 · Drug: Nivolumab

  • Experimental
    Part 2 Cohort 2: TRK-950+Nivolumab

    * Nivolumab-eligible solid tumor * Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1 and 15. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion.

    Biological: TRK-950 · Drug: Nivolumab

  • Experimental
    Part 3: TRK-950

    * Melanoma * TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle.

    Biological: TRK-950

Interventions

  • BiologicalTRK-950

    5 or 10 mg/kg administered intravenously over 60 minutes (weekly)

  • BiologicalTRK-950

    10 mg/kg administered intravenously over 60 minutes (weekly)

  • BiologicalTRK-950

    20 mg/kg administered intravenously over 60 minutes (bi-weekly)

  • 240 mg administered intravenously over 30 minutes (bi-weekly)

  • BiologicalTRK-950

    10 mg/kg administered Intravenously over 60 minutes (weekly)

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicities (DLTs) (Part 1 and 2)

    Number of participants with DLTs will be determined.

    Time frame: Up to Day 28

  2. Number of participants with adverse events (AEs) (Part 1 and 2)

    Number of participants with AEs will be assessed.

    Time frame: through study completion, an average of 1 year

  3. Number of participants with adverse events of special interest (AESIs) (Part 1 and 2)

    Number of participants with AESIs will be assessed.

    Time frame: through study completion, an average of 1 year

  4. Number of participants with serious adverse events (SAEs) (Part 1 and 2)

    Number of participants with SAEs will be assessed.

    Time frame: through study completion, an average of 1 year

  5. Objective response rate (ORR) (Part 3)

    Objective response rate (ORR) is defined as the percentage of patients who achieved either complete response (CR) or partial response (PR) as assessed by independent central review (ICR) per RECIST Version 1.1.

    Time frame: Up to approximately 12 months

Secondary outcomes

  1. Area under the concentration curve (AUC) of TRK-950 (Part 1 and 2)

    Time frame: through study completion, an average of 1 year

  2. Maximum plasma concentration (Cmax) of TRK-950 (Part 1 and 2)

    Time frame: through study completion, an average of 1 year

  3. Time to maximum plasma concentration (Tmax) of TRK-950 (Part 1 and 2)

    Time frame: through study completion, an average of 1 year

  4. Terminal elimination half life (t1/2) of TRK-950 (Part 1 and 2)

    Time frame: through study completion, an average of 1 year

  5. Total body clearance (CL) of TRK-950 (Part 1 and 2)

    Time frame: through study completion, an average of 1 year

  6. Apparent volume of distribution (Vd) of TRK-950 (Part 1 and 2)

    Time frame: through study completion, an average of 1 year

  7. Area under the concentration curve (AUC) of Nivolumab (Part 2 only)

    Time frame: through study completion, an average of 1 year

  8. Overall survival (OS) (Part 3)

    Overall survival (OS) is defined as time from the first date of TRK-950 administration until the date of death due to any cause.

    Time frame: Up to approximately 12 months

  9. Progression-free survival (PFS) (Part 3)

    Progression-free survival (PFS) is defined as time from the first date of TRK-950 administration until progression per RECIST Version 1.1, or death due to any cause.

    Time frame: Up to approximately 12 months

  10. Best overall response (BOR) (Part 3)

    Best overall response (BOR) is defined as the best response among all responses at each time point from the first date of TRK-950 administration until progression per RECIST Version 1.1.

    Time frame: Up to approximately 12 months

  11. Disease control rate (DCR) (Part 3)

    Disease control rate (DCR) is defined as the percentage of patients with BOR of CR or PR or stable disease (SD) per RECIST Version 1.1.

    Time frame: Up to approximately 12 months

  12. Duration of response (DOR) (Part 3)

    Duration of response (DOR) is defined as the duration between the date of first documented response (CR or PR) and the date of progression per RECIST Version 1.1, or death due to any cause.

    Time frame: Up to approximately 12 months

  13. Tumor change rate (Part 3)

    Tumor change rate is defined as the percentage change in the sum of the longest diameters of target lesions, as assessed per RECIST Version 1.1, compared to baseline obtained at screening.

    Time frame: Up to approximately 12 months

07

Study locations

10 of 10 sites recruiting
08

References and documents

Publications

  • Koyama T, Yonemori K, Sato J, Katsuya Y, Okada M, Yoshida T, Okano F, Yamamoto N. A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. Invest New Drugs. 2026 Apr 14. doi: 10.1007/s10637-026-01609-z. Online ahead of print. PubMed 41979863 ↗
  • Okano F, Saito T, Minamida Y, Kobayashi S, Ido T, Miyauchi Y, Wasai U, Akazawa D, Kume M, Ishibashi M, Jiang K, Aicher A, Heeschen C, Yonehara T. Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. Cancer Res Commun. 2023 Apr 18;3(4):640-658. doi: 10.1158/2767-9764.CRC-22-0310. eCollection 2023 Apr. PubMed 37082579 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Mar 2028, 68 months after the start.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 84. This study's planned 68 months is above that.

Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2027 → Mar 2028 and completion Dec 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 21, 2022
StartActual
Jul 6, 2022
Primary completionEst.
Mar 31, 2028was Dec 2027
CompletionEst.
Mar 31, 2028was Dec 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2027→Mar 31, 2028
Oct 8, 2026
Study completion
Dec 2027→Mar 31, 2028
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Dec 2027→Mar 31, 2028
    Study completion Dec 2027→Mar 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05423262
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Jul 6, 2022
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Toray Contact for Clinical Trial Information
Contact
npdd-clinical.toray.mb@mail.toray
+81467-32-9948

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK-950

Start the discussion